Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Crawford

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cold Spring Harbor Molecular Case Studies|April 3, 2020
Defining an embryonal rhabdomyosarcoma endotypeCora A Ricker, Kenneth Crawford, Kevin Matlock, et al.
Protein Expression and Purification|March 31, 2015
Expression, purification and characterization of inactive and active forms of ERK2 from insect expression systemKelly Yan, Hanne Merritt, Kenneth Crawford, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2006
Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studiesXiaodong Lin, Jeremy M Murray, Alice C Rico, et al.
Molecular Cancer Research : MCR|February 21, 2014
Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancersIda Aronchik, Brent A Appleton, Stephen E Basham, et al.
Journal of Molecular Biology|April 24, 2017
Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR InhibitorsYipin Lu, Mark Knapp, Kenneth Crawford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli-Ann Monaco, Scott Delach, Jing Yuan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating CancerMatthew T Burger, Sabina Pecchi, Allan Wagman, et al.
Plos One|April 7, 2017
Inhibition of prenylated KRAS in a lipid environmentJohanna M Jansen, Charles Wartchow, Wolfgang Jahnke, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cold Spring Harbor Molecular Case Studies|April 3, 2020
Defining an embryonal rhabdomyosarcoma endotypeCora A Ricker, Kenneth Crawford, Kevin Matlock, et al.
Protein Expression and Purification|March 31, 2015
Expression, purification and characterization of inactive and active forms of ERK2 from insect expression systemKelly Yan, Hanne Merritt, Kenneth Crawford, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2006
Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studiesXiaodong Lin, Jeremy M Murray, Alice C Rico, et al.
Molecular Cancer Research : MCR|February 21, 2014
Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancersIda Aronchik, Brent A Appleton, Stephen E Basham, et al.
Journal of Molecular Biology|April 24, 2017
Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR InhibitorsYipin Lu, Mark Knapp, Kenneth Crawford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli-Ann Monaco, Scott Delach, Jing Yuan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating CancerMatthew T Burger, Sabina Pecchi, Allan Wagman, et al.
Plos One|April 7, 2017
Inhibition of prenylated KRAS in a lipid environmentJohanna M Jansen, Charles Wartchow, Wolfgang Jahnke, et al.
Science (New York, N.Y.)|February 26, 2016
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Konstantinos J Mavrakis, E Robert McDonald, Michael R Schlabach, et al.
Pageof 1